Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Costs Down 1.6% in Municipal Hospitals in FY2008
August 24, 2009
- Top-Four Wholesalers' FY2009 1st Qtr Business Roundup
August 24, 2009
- GE Healthcare, Terumo Agree on Joint Marketing
August 24, 2009
- Makers' FY2009 1st Qtr Business Roundup
August 24, 2009
- GE Healthcare Integrates Two Subsidiaries to Create GE Healthcare Japan
August 24, 2009
- AZ, Astellas to Copromote Symbicort in Japan
August 24, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 24, 2009
- Daiichi Sankyo, Eli Lilly Launch Effient in the US
August 24, 2009
- JACDS Promotes Class 1 OTC Drugs to Increase Sales by 50%
August 24, 2009
- DSP to File NDA for Lurasidone in US in 1st Half of 2010
August 24, 2009
- Emergency Delivery Rates Achieve Goal at 83% in FY2008
August 24, 2009
- Zeria to Acquire Tillotts
August 24, 2009
- REGULATORY NEWS IN BRIEF
August 10, 2009
- Zeria to Acquire Tillotts
August 10, 2009
- Introduce Financial Incentives to Promote Use of Generics: Mr Sawai of JGA
August 10, 2009
- Erbitux Sales to Exceed 1 Bil. Euro Mark
August 10, 2009
- Combination Drugs Interfere with Promotion of Generics: JSHP
August 10, 2009
- No. 3 and No. 4 CSOs to Merge
August 10, 2009
- Establish Regional Networks to Promote Use of Generics: Mr Kinoshita
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 10, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…